p-Nitrophenyl-β-D-galactopyranosid

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: p-Nitrophenyl-β-D-galactopyranosid
• 英文别名: 2-Np-β-D-galactopyranoside；(2R,3R,4S,5R,6R)-6-(hydroxymethyl)-3-(4-nitrophenoxy)oxane-2,4,5-triol
• 化学式: C₁₂H₁₅NO₈
• 分子量: 301.253
• InChiKey: LZRUQOCSKQTCCJ-YBXAARCKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  145
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  2-乙酰氨基-2-脱氧-D-吡喃半乳糖 、 N-乙酰神经氨酸 、 p-Nitrophenyl-β-D-galactopyranosid 在 Triton-X-100 、 Na-cacodylate buffer 、 potassium chloride 、 phosphoenolpyruvic acid monopotassium salt 、 5'-胞苷酸 、 胞苷-5’-三磷酸 、 magnesium chloride 、 manganese(ll) chloride 作用下， 以 水 为溶剂， 反应 82.0h， 生成 (2S,4S,5R,6R)-5-乙酰氨基-2-[(2R,3R,4S,5S,6R)-2-[(2R,3R,4R,5R,6R)-3-乙酰氨基-2,5-二羟基-6-(羟基甲基)四氢吡喃-4-基]氧基-3,5-二羟基-6-(羟基甲基)四氢吡喃-4-基]氧基-4-羟基-6-[(1R,2R)-1,2,3-三羟基丙基]四氢吡喃-2-羧酸 、 O-(5-acetamido-3,5-dideoxy-α-D-glycero-D-galacto-2-nonulopyranosylonic-acid)-(2-3)-O-β-D-galactopyranosyl-(1-3)-2-acetamido-2-deoxy-α-D-galactopyranose
  参考文献：
  名称：

  Kren, Vladimir; Thiem, Joachim, Angewandte Chemie, 1995, vol. 107, # 8, p. 979 - 981

  摘要：

  DOI：

文献信息

• RADIOLABELED DRUG
  申请人：National University Corporation Chiba University

  公开号：US20190091353A1

  公开（公告）日：2019-03-28

  The present invention relates to a compound, etc. capable of providing a radiolabeled drug that can reduce the renal accumulation thereof in the early stage after the administration thereof. [1] A compound, etc. represented by the formula (1), [2] a compound, etc. containing the compound, etc. according to the item [1] and a target molecule recognition element bonded thereto, [3] a metal complex compound, etc. containing one kind of a metal selected from a radioactive metal and a radioactive atom-labeled metal, and the compound, etc. according to the item [1] or [2], which is coordinated to the metal, [4] a drug for preparing a radiolabeled drug, containing the compound, etc. according to the item [1] or [2], [5] use of the compound, etc. according to the item [1] or [2], for producing a radiolabeled drug, [6] a radiolabeled drug containing the metal complex compound, etc. according to the item [3], and [7] a radiodiagnostic imaging agent containing the metal complex compound, etc. according to the item [3]:

  本发明涉及一种化合物等，能够提供一种放射性标记药物，该药物在给药后的早期阶段能够减少其在肾脏中的积累。【1】一种由式（1）表示的化合物等，【2】一种包含根据项目【1】中的化合物等及与之结合的靶分子识别元素的化合物等，【3】一种金属配合物等，包含从放射性金属和放射性原子标记金属中选择的一种金属，并与根据项目【1】或【2】的化合物等配位的化合物等，【4】用于制备放射性标记药物的药物，包含根据项目【1】或【2】的化合物等，【5】使用根据项目【1】或【2】的化合物等，用于生产放射性标记药物，【6】包含根据项目【3】的金属配合物等的放射性标记药物，以及【7】包含根据项目【3】的金属配合物等的放射诊断成像剂。
• CHIRAL BINUCLEAR METAL COMPLEXES FOR STEREOSELECTIVE GLYCOSIDE HYDROLYSIS OF SACCHARIDES
  申请人：BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS

  公开号：US20170275303A1

  公开（公告）日：2017-09-28

  Disclosed herein is a class of chiral binuclear metal complexes for stereoselective glycoside hydrolysis of saccharides, and more particular chiral binuclear transition metal complex catalysts that discriminate epimeric glycosides and α- and β-glycosidic bonds of saccharides in aqueous solutions at near physiological pHs. The chiral binuclear metal complexes include a Schiff-base-type ligand derived from a chiral diamino building block, and a binuclear transition metal core, each which can be varied for selectivity. The metal core is a Lewis-acidic metal ion, such as copper, zinc, lanthanum, iron and nickel. The Schiff-base may be a reduced or non-reduced Schiff-base derived from aliphatic linear, aliphatic cyclic diamino alcohols or aromatic aldehydes. The ligand can be a penta- or heptadentate ligand derived from pyridinecarbaldehydes, benzaldehydes, linear or cyclic diamines or diamino alcohols.

  本文揭示了一类手性双核金属配合物，用于在接近生理pH值的水溶液中对糖类进行立体选择性水解，更具体地说，是手性双核过渡金属配合物催化剂，可以区分糖类的对映异构体和α-和β-糖苷键。这些手性双核金属配合物包括来源于手性二胺建筑块的席夫碱型配体和双核过渡金属核心，每个都可以根据选择性进行变化。金属核心是一种路易斯酸性金属离子，例如铜、锌、镧、铁和镍。席夫碱可以是从脂肪线性、脂肪环状二胺醇或芳香醛衍生的还原或非还原的席夫碱。配体可以是从吡啶甲醛、苯甲醛、线性或环状二胺或二胺醇衍生的五齿或七齿配体。
• Sugar-derived gellant for hydrogel formation
  申请人：——

  公开号：US20040014683A1

  公开（公告）日：2004-01-22

  A gelatinizer having gel-forming capability in both organic solvents and water, is provided. This invention is a hydrogelatinizer represented by: 1 (where, A is a sugar residue, and R is an alkyl group).

  提供了一种在有机溶剂和水中都具有凝胶形成能力的凝胶化剂。该发明是一种水凝胶化剂，其表示为：1（其中，A是糖残基，R是烷基）。
• BETA-GALACTOSIDASE DERIVED FROM BACILLUS CIRCULANS
  申请人：Katase Toru

  公开号：US20120135468A1

  公开（公告）日：2012-05-31

  Disclosed is a novel β-galactosidase. Specifically disclosed are a β-galactosidase derived from Bacillus circulans and a gene for the β-galactosidase. The β-galactosidase can be used, for example, in the production of milk, dairy products, fermented dairy products, galacto-oligosaccharides or supplements for foods.

  本发明涉及一种新型β-半乳糖苷酶。具体揭示了从环状芽孢杆菌中得到的β-半乳糖苷酶及其基因。该β-半乳糖苷酶可以用于牛奶、乳制品、发酵乳制品、半乳寡糖或食品补充剂等的生产中。
• NOVEL GLYCOSYL HYDROLASE WITH BETA-XYLOSIDASE AND BETA-GLUCOSIDASE ACTIVITIES AND USES THEREOF
  申请人：Zhu Ping

  公开号：US20130130330A1

  公开（公告）日：2013-05-23

  A novel glycosyl hydrolase with activities of beta-xylosidase and beta-glucosidase is provided. Said glycosyl hydrolase can convert 7-xylosyltaxane compounds to 7-hydroxyltaxane compounds.

  提供了一种新型的糖基水解酶，具有β-木糖苷酶和β-葡萄糖苷酶的活性。该糖基水解酶可以将7-木糖基紫杉烷类化合物转化为7-羟基紫杉烷类化合物。